Aurinia Pharmaceuticals Company Profile (NASDAQ:AUPH)

About Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AUPH
  • CUSIP: N/A
  • Web: www.auriniapharma.com
Capitalization:
  • Market Cap: $542.1 million
  • Outstanding Shares: 83,272,000
Average Prices:
  • 50 Day Moving Avg: $6.35
  • 200 Day Moving Avg: $5.86
  • 52 Week Range: $1.74 - $10.54
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $147,000.00
  • Price / Sales: 3,636.78
  • Book Value: $2.10 per share
  • Price / Book: 3.06
Profitability:
  • EBIDTA: ($26,510,000.00)
  • Net Margins: -48,278.23%
  • Return on Equity: -50.53%
  • Return on Assets: -36.88%
Debt:
  • Current Ratio: 24.60%
  • Quick Ratio: 24.61%
Misc:
  • Average Volume: 2.42 million shs.
  • Beta: 2.62
  • Short Ratio: 3.34
 
Frequently Asked Questions for Aurinia Pharmaceuticals (NASDAQ:AUPH)

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Monday, May, 15th. The company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.08. The firm had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.53% and a negative net margin of 48,278.23%. View Aurinia Pharmaceuticals' Earnings History.

Where is Aurinia Pharmaceuticals' stock going? Where will Aurinia Pharmaceuticals' stock price be in 2017?

7 brokers have issued twelve-month target prices for Aurinia Pharmaceuticals' stock. Their forecasts range from $8.00 to $14.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $10.67 in the next year. View Analyst Ratings for Aurinia Pharmaceuticals.

What are analysts saying about Aurinia Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (6/27/2017)
  • 2. FBR & Co analysts commented, "We increase our price target 22% from $9 to $11, as we think that with a balance sheet bolstered by a public offering that we estimate raised up to $161M in net proceeds, AUPH is now in a strong position to independently advance voclosporin (VCS), its investigational therapy for patients with active lupus nephritis (LN), into Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by major pharmaceutical companies (Big Pharma) hungry for the next multi-billiondollar drug (FBR projects VCS could achieve >$2B in annual peak sales), we look for AUPH to receive an acquisition bid from a Big Pharma company in the next six to nine months, with an initial bid of $10 per share reasonable. We think AUPH is more likely to look to sign a partnership agreement; therefore, we look for a deal worth $500M to $700M in up-front and milestone payments to AUPH. We reiterate our Outperform rating." (3/22/2017)

Who are some of Aurinia Pharmaceuticals' key competitors?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:

  • Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer
  • Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
  • Michael R. Martin, Chief Operating Officer
  • Neil Solomons M.D., Chief Marketing Officer
  • Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
  • Robert B. Huizinga, Vice President - Clinical Affairs
  • Lawrence D. Mandt, Vice President - Regulatory and Quality
  • George M. Milne Jr., Ph.D., Director
  • Lorin Jeffry Randall, Director
  • Benjamin Rovinski Ph.D., Independent Director

Who owns Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include OTA Financial Group L.P. (0.21%), Creative Planning (0.20%), Cutler Capital Management LLC (0.04%) and State Treasurer State of Michigan (0.03%). View Institutional Ownership Trends for Aurinia Pharmaceuticals.

Who sold Aurinia Pharmaceuticals stock? Who is selling Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan. View Insider Buying and Selling for Aurinia Pharmaceuticals.

Who bought Aurinia Pharmaceuticals stock? Who is buying Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning and Cutler Capital Management LLC. View Insider Buying and Selling for Aurinia Pharmaceuticals.

How do I buy Aurinia Pharmaceuticals stock?

Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $6.42.


MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.67 (66.15% upside)

Analysts' Ratings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017HC WainwrightLower Price TargetBuy -> Buy$12.00 -> $10.00LowView Rating Details
4/21/2017Cantor FitzgeraldReiterated RatingBuy$14.00HighView Rating Details
4/11/2017FBR & CoReiterated RatingOutperformMediumView Rating Details
3/11/2017Canaccord GenuitySet Price TargetBuy$10.00HighView Rating Details
3/2/2017Leerink SwannBoost Price TargetOutperform$7.00 -> $11.00N/AView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
11/2/2016MackieReiterated RatingBuy$8.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Earnings by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Earnings History by Quarter for Aurinia Pharmaceuticals (NASDAQ AUPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/20173/31/2017($0.12)($0.20)$0.05 million$0.03 millionViewN/AView Earnings Details
3/9/2017Q4($0.12)($0.22)$0.06 million$0.03 millionViewN/AView Earnings Details
5/11/2016Q1($0.14)($0.13)$0.10 million$0.06 millionViewN/AView Earnings Details
3/18/2016Q4($0.16)($0.16)$0.09 million$0.06 millionViewN/AView Earnings Details
3/30/2015Q4 2014($0.11)($0.15)$0.10 million$0.07 millionViewN/AView Earnings Details
11/12/2014Q3 14($0.08)$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)
2017 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.13)($0.10)($0.12)
Q2 20172($0.13)($0.11)($0.12)
Q3 20172($0.14)($0.12)($0.13)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Latest Headlines for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Source:
DateHeadline
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 7:56 AM
finance.yahoo.com logoAurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : July 17, 2017
finance.yahoo.com - July 17 at 12:31 PM
americanbankingnews.com logo Analysts Expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Will Announce Quarterly Sales of $60,000.00
www.americanbankingnews.com - July 15 at 9:42 AM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (NASDAQ:AUPH) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 13 at 8:12 AM
businesswire.com logoAurinia Resolves Temporary Non-Compliance with Nasdaq's Audit Committee Composition Rule - Business Wire (press release)
www.businesswire.com - July 13 at 2:46 AM
seekingalpha.com logoInstitutional Ownership Swells At Well-Funded Aurinia Pharmaceuticals - Seeking Alpha
seekingalpha.com - July 11 at 4:28 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock
finance.yahoo.com - July 10 at 4:11 PM
seekingalpha.com logoAurinia Pharmaceuticals: Phase III Design Gleaned From Phase II Study
seekingalpha.com - July 6 at 5:32 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - June 27 at 9:34 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 8:02 AM
finance.yahoo.com logoAurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC
finance.yahoo.com - June 21 at 4:40 PM
americanbankingnews.com logo$50,000.00 in Sales Expected for Aurinia Pharmaceuticals Inc (AUPH) This Quarter
www.americanbankingnews.com - June 21 at 11:48 AM
nasdaq.com logoDo Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't? - Nasdaq
www.nasdaq.com - June 20 at 9:25 PM
zacks.com logoDo Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
www.zacks.com - June 20 at 4:22 PM
finance.yahoo.com logoDo Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
finance.yahoo.com - June 20 at 4:22 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Expected to Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - June 19 at 7:48 AM
benzinga.com logoOngoing Aurinia Pharmaceuticals Study Results Boost Shares Higher - Benzinga
www.benzinga.com - June 16 at 9:28 PM
finance.yahoo.com logoVoclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017
finance.yahoo.com - June 16 at 4:25 PM
finance.yahoo.com logoAurinia Pharma Rises Following Updated Mid-Stage Results
finance.yahoo.com - June 16 at 4:25 PM
feeds.benzinga.com logoOngoing Aurinia Pharmaceuticals Study Results Boost Shares Higher
feeds.benzinga.com - June 16 at 9:22 AM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Expected to Post FY2017 Earnings of ($1.15) Per Share
www.americanbankingnews.com - June 9 at 8:58 AM
prnewswire.com logoTechnical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma
www.prnewswire.com - June 8 at 8:24 AM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Presents Additional Data from Phase Iib Aura-Lv Study - StreetInsider.com
www.streetinsider.com - June 6 at 3:51 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Presents Additional Data from Phase IIB AURA-LV Study at ERA-EDTA Congress - StreetInsider.com
www.streetinsider.com - June 5 at 1:03 PM
finance.yahoo.com logoAurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks
finance.yahoo.com - June 5 at 1:03 PM
finance.yahoo.com logoAurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 5:02 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) To Participate In Late Breaking Oral Presentations At 2 Upcoming Scientific ... - StreetInsider.com
www.streetinsider.com - May 31 at 3:44 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) To Participate In Late Breaking Oral Presentations At 2 Upcoming Scientific Conferences
www.streetinsider.com - May 31 at 10:50 AM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 8:00 AM
americanbankingnews.com logoLeerink Swann Weighs in on Aurinia Pharmaceuticals Inc's Q2 2017 Earnings (AUPH)
www.americanbankingnews.com - May 18 at 8:21 AM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Given New $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 18 at 8:10 AM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Doses First Patient in AURORA Phase 3 Trial of Voclosporin in LN
www.streetinsider.com - May 17 at 8:46 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Posts Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - May 16 at 3:48 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics
finance.yahoo.com - May 16 at 12:27 PM
finance.yahoo.com logoAurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
finance.yahoo.com - May 15 at 4:13 PM
finance.yahoo.com logoAurinia reports 1Q loss
finance.yahoo.com - May 15 at 4:13 PM
finance.yahoo.com logoAurinia Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AUPH) : May 11, 2017
finance.yahoo.com - May 11 at 9:10 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Short Interest Up 22.2% in April
www.americanbankingnews.com - May 11 at 8:36 AM
nasdaq.com logoIs a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season? - Nasdaq
www.nasdaq.com - May 10 at 8:54 PM
zacks.com logoIs a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
www.zacks.com - May 9 at 9:07 AM
finance.yahoo.com logoPharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
finance.yahoo.com - May 9 at 9:07 AM
finance.yahoo.com logoAurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : May 9, 2017
finance.yahoo.com - May 9 at 9:07 AM
seekingalpha.com logoAurinia Pharmaceuticals Is A Top Pick For H2 2017 - Seeking Alpha
seekingalpha.com - May 2 at 3:45 PM
americanbankingnews.com logoAurinia Pharmaceuticals (AUPH) Receiving Somewhat Negative Media Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 12:20 PM
finance.yahoo.com logo3 Best Biotech Stocks During Trump's First 100 Days
finance.yahoo.com - May 1 at 3:45 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - May 1 at 11:03 AM
americanbankingnews.com logoAurinia Pharmaceuticals (AUPH) Receives Daily Media Impact Rating of 0.20
www.americanbankingnews.com - April 29 at 9:58 AM
americanbankingnews.com logoAurinia Pharmaceuticals (AUPH) Earning Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 26 at 4:54 PM
finance.yahoo.com logoAurinia to Present at Bloom Burton & Co. Healthcare Conference
finance.yahoo.com - April 26 at 10:19 AM
americanbankingnews.com logoAurinia Pharmaceuticals (AUPH) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 23 at 10:17 AM

Social

Chart

Aurinia Pharmaceuticals (AUPH) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff